Literature DB >> 14691345

Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.

Clive H Wilder-Smith1, Kerstin Röhss, Catharina Nilsson-Pieschl, Ola Junghard, Lars Nyman.   

Abstract

AIM: To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers.
METHODS: In two standardized, randomized crossover studies, Helicobacter pylori negative healthy volunteers (study A: 19 males, 5 females; study B: 13 males, 10 females) received esomeprazole 40 mg and either lansoprazole 30 mg (study A) or rabeprazole 20 mg (study B) orally once daily in the morning for 5 days. Continuous 24-hour intragastric pH recording was performed on day 5.
RESULTS: The intragastric pH was maintained >4 for 65% (95% CI 59.5-71.3) of the 24-hour period with esomeprazole and for 53% of the time (95% CI 47.0-58.9) with lansoprazole in study A (p < 0.001). In study B, the proportion of time with pH >4 was 61% (95% CI 53.6-68.3) with esomeprazole versus 45% (95% CI 37.7-52.5) with rabeprazole (p = 0.005). The 24-hour median pH and the proportion of volunteers with intragastric pH >4 for > or =12 h and > or =16 h were significantly higher with esomeprazole than with either lansoprazole or rabeprazole.
CONCLUSION: Esomeprazole 40 mg provides significantly more effective and more sustained gastric acid control than lansoprazole 30 mg or rabeprazole 20 mg in healthy volunteers. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691345     DOI: 10.1159/000075697

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  15 in total

Review 1.  Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Authors:  Jan C Becker; Wolfram Domschke; Thorsten Pohle
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

Review 2.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.

Authors:  Jocelyn Zhou; Michelle Quinlan; Kelli Glenn; Hildegard Boss; Franck Picard; Henry Castro; Dalila Sellami
Journal:  Br J Clin Pharmacol       Date:  2016-07-13       Impact factor: 4.335

Review 4.  Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.

Authors:  J Enrique Domínguez-Muñoz; Miguel Sobrino
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.

Authors:  K M Fock; E K Teo; T L Ang; T S Chua; T M Ng; Y L Tan
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

Review 6.  Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Kate McKeage; Stephanie K A Blick; Jamie D Croxtall; Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

8.  Efficacy of esomeprazole in treating acid-related diseases in Japanese populations.

Authors:  Mitsushige Sugimoto; Takahisa Furuta
Journal:  Clin Exp Gastroenterol       Date:  2012-05-14

Review 9.  Current perspectives in NSAID-induced gastropathy.

Authors:  Mau Sinha; Lovely Gautam; Prakash Kumar Shukla; Punit Kaur; Sujata Sharma; Tej P Singh
Journal:  Mediators Inflamm       Date:  2013-03-12       Impact factor: 4.711

10.  Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.

Authors:  Jai Moo Shin; Nayoung Kim
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.